>_ QFI Terminal
TerminalStocks › HURA

TuHURA Biosciences, Inc. (HURA) Stock

Healthcare · Biotechnology · US
$2.10 +0.48%
Last updated Sep 20, 2026 14:59 UTC

HURA Key Statistics

Market Cap$133.73M
P/E (TTM)-3.89
P/S (TTM)
P/B (TTM)7.26
Revenue (TTM)$0.00
EPS (TTM)$-0.54
Dividend Yield
ROE (TTM)-154.32%
Net Margin0.00%
Gross Margin0.00%
52W High$3.43
52W Low$0.41
Analyst ViewBuy
Price Target
Employees22
Volume174,704

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

CEO: James A. Bianco. Company website

HURA — Frequently Asked Questions

What is the HURA stock price today?

TuHURA Biosciences, Inc. (HURA) trades at $2.10, up 0.48% on the day, as of Sep 20, 2026 14:59 UTC.

What is TuHURA Biosciences, Inc.'s market cap?

TuHURA Biosciences, Inc. has a market capitalisation of $133.73M, calculated from the live HURA share price and shares outstanding.

What is the P/E ratio of HURA?

HURA has no meaningful price-to-earnings ratio: TuHURA Biosciences, Inc. lost $0.54 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does TuHURA Biosciences, Inc. make?

TuHURA Biosciences, Inc. generated revenue of $0.00 over the trailing twelve months.

What is the 52-week range for HURA?

HURA has traded between $0.41 and $3.43 over the past 52 weeks, and the last price is 38.8% below that high.

Is TuHURA Biosciences, Inc. profitable?

Yes. TuHURA Biosciences, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.

What is the analyst price target for HURA?

Wall Street analysts rate HURA Buy.

What sector is TuHURA Biosciences, Inc. in?

TuHURA Biosciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.

Who is the CEO of TuHURA Biosciences, Inc.?

James A. Bianco is the chief executive of TuHURA Biosciences, Inc., which employs 22 people.

Where can I track HURA in real time?

QFI Terminal shows HURA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See HURA live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open HURA in Terminal See plans

Biotechnology stocks

REGN Regeneron Pharmaceuticals, Inc. VRTX Vertex Pharmaceuticals Incorporated ONC BeOne Medicines AG ARGX argenx SE INCY Incyte Corporation ALNY Alnylam Pharmaceuticals, Inc. JAZZ Jazz Pharmaceuticals plc GMAB Genmab A/S

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.